General
Preferred name
NEDOCROMIL
Synonyms
Tilade ()
NEDOCROMIL SODIUM ()
nedocromil sodium, Allergan ()
NEDOCROMIL CALCIUM ()
FPL 59002 ()
FPL-59002 ()
Alocril ()
Nedocromil disodium salt ()
Tayled ()
FPL-59002KP ()
Tilarin ()
Rapitil ()
FPL 59002KP ()
FPL-59002KC ()
FPL 59002KC ()
Nedocromil (sodium salt) ()
P&D ID
PD010062
CAS
69049-73-6
69049-74-7
101626-68-0
Tags
available
drug candidate
drug
Approved by
FDA
First approval
1992
Drug Status
investigational
approved
Max Phase
Phase 4
Drug indication
Anti-Allergic (prophylactic)
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Nedocromil is considered to be a mast cell stabilising drug. Chemically it belongs to the benzopyrone family of compounds. In the US, production of inhaled nedocromil was terminated in 2008. (GtoPdb)
DESCRIPTION Nedocromil is an inhaled anti-inflammatory agent for the preventive management of asthma. (BOC Sciences Bioactive Compounds)
Compound Sets
16
BOC Sciences Bioactive Compounds
nedocromil-cas-69049-73-6-item-84-75297
Cayman Chemical Bioactives
24005
ChEMBL Approved Drugs
CHEMBL746
CHEMBL915
ChEMBL Drugs
CHEMBL746
CHEMBL915
CHEMBL2105133
Drug Repurposing Hub
DrugBank
DB00716
DrugBank Approved Drugs
DB00716
DrugCentral
1889
DrugCentral Approved Drugs
1889
DrugMatrix
Guide to Pharmacology
7607
MedChem Express Bioactive Compound Library
HY-13448
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
0B535E0BN0
NPC Screening Collection
ReFrame library
External IDs
66
Properties
(calculated by RDKit )
Molecular Weight
371.1
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
5
Ring Count
3
Aromatic Ring Count
3
cLogP
2.48
TPSA
126.81
Fraction CSP3
0.26
Chiral centers
0.0
Largest ring
6.0
QED
0.66
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Indication
itching, conjunctivitis
Disease Area
neurology/psychiatry, ophthalmology
Target
CYSLTR1, CYSLTR2, FPR1, HSP90AA1, PTGDR
Histamine Receptor
Leukotriene Receptor
Prostaglandin Receptor
MOA
Histamine Receptor antagonist
Biosynthetic Origin
Other (Shikimate)
Therapeutic Indication
Nootropic
Therapeutic Class
CNS & PNS
Pathway
GPCR/G protein
Immunology/Inflammation
Neuronal Signaling
Source data